Lindsay Orton, PharmD, BCOP

Panelists discuss how second-line therapy selection and individualized care strategies are essential in chronic graft-vs-host disease (cGVHD) management, emphasizing the need to reduce steroid-related toxicity, address patient-specific factors, and leverage pharmacist expertise to optimize outcomes.

Panelists discuss how early diagnosis, evolving treatment strategies, and pharmacist-led interventions are advancing chronic graft-vs-host disease (cGVHD) management by addressing unmet needs, improving care coordination, and enhancing patient access to emerging therapies.